Phase 2 Advanced Breast Cancer trials recruiting now

All Advanced Breast Cancer trials, every phase

Other phases for Advanced Breast Cancer

Phase 2 Advanced Breast Cancer trials

• A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
  NCT07540533 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
  NCT07130383 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
  NCT06176534 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
  NCT07180082 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
  NCT06298084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
  NCT06656624 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
  NCT07037199 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
  NCT05949541 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
  NCT05530057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
  NCT05536128 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
  NCT06193525 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
  NCT05933395 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
  NCT07180160 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
  NCT07602907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
  NCT07259226 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
  NCT04965766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
  NCT06993844 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
  NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
  NCT06486883 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 79 locations
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
  NCT06263543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
  NCT06433609 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
  NCT07427394 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 6 locations
• Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
  NCT04892693 · Phase: Phase 2 · Ages: 19 Years and older · Sex: Female · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.